Antitumor effects of flavopiridol on human uterine leiomyoma in vitro and in a xenograft model

Reproductive Sciences

Volumn 21, Issue 9, 2014, Pages 1153-1160

  Lee, Hyun Gyo ^a   Baek, Jong Woo ^b   Shin, So Jin ^a   Kwon, Sang Hoon ^a   Cha, Soon Do ^a   Park, Won Jin ^a   Chung, Rosa ^a   Choi, Eun Som ^a   Lee, Gun Ho ^b   Cho, Chi Heum ^a  

^a Keimyung University School of Medicine   (South Korea)

^b Cha University   (South Korea)

Author keywords

flavopiridol; leiomyoma; p27kip1; uterus; xenograft

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FLAVOPIRIDOL; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN; ANTINEOPLASTIC AGENT; FLAVONOID; PIPERIDINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIMARY CELL CULTURE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION; UTERUS MYOMA; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; KNOCKOUT MOUSE; LEIOMYOMA; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL CULTURE; UTERINE NEOPLASMS;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLAVONOIDS; HUMANS; LEIOMYOMA; MICE; MICE, KNOCKOUT; MIDDLE AGED; PIPERIDINES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907197386     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719114525266     Document Type: Article

References (38)

1. Catherino WH, Malik M. Uterine leiomyoma express a molecular pattern that lowers retinoic acid exposure. Fertil Steril. 2007;87(6):1388-1398.
2. Corbin A, Beattie CW. Inhibition of the pre-ovulatory proestrous gonadotropin surge, ovulation and pregnancy with a peptide analogue of luteinizing hormone releasing hormone. Endocr Res Commun. 1975;2(1):1-23.
3. Flierman PA, Oberye JJ, Van der Hulst VP, de Blok S. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix. BJOG. 2005;112(5):638-642.
4. Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421-432.
5. Grant S, Dent P. Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name? Mol Cancer Ther. 2004;3(7):873-875.
6. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005;106(7):2513-2519.
7. Newcomb EW, Tamasdan C, Entzminger Y, et al. Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor. Cell Cycle. 2003;2(3):243-250.
8. Bonvini P, Zorzi E, Mussolin L, et al. The effect of the cyclindependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. Haematologica . 2009;94(7):944-955.
9. Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs. 1999;17(3):313-320.
10. Fredersdorf S, Burns J, Milne AM, et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A. 1997;94(12):6380-6385.
11. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res . 1997;57(16):3381-3385.
12. Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol. 1998;11(2):169-174.
13. kip1 controls growth and cell cycle progression in human uterine leiomyoma. J Korean Medi Sci. 2008;23(4):667-673.
14. Shiozawa T, Horiuchi A, Kato K, et al. Up-regulation of p27Kip1 by progestins is involved in the growth suppression of the normal and malignant human endometrial glandular cells. Endocrinology. 2001;142(10):4182-4188.
15. Mayer F, Mueller S, Malenke E, Kuczyk M, Hartmann JT, Bokemeyer C. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Invest New Drugs. 2005;23(3):205-211.
16. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996;56(13):2973-2978.
17. Park KH, Seol JY, Yoo CG, et al. Adenovirus expressing p27(Kip1) induces growth arrest of lung cancer cell lines and suppresses the growth of established lung cancer xenografts. Lung Cancer. 2001;31(2-3):149-155.
18. Drosch M, Bullerdiek J, Zollner TM, Prinz F, Koch M, Schmidt N. A novel mouse model that closely mimics human uterine leiomyomas. Fertil Steril. 2013;99(3):927-935.
19. Maruo T, Ohara N, Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Report Update. 2004;10(3):207-220.
20. Pollw K, Sinnecker G, Boquoi E, Pollow B. In vitro conversion of estradiol-17 into estrone in normal human myometrium and leiomyoma. J Clin Chem Clin Biochem. 1978;16(9):493-502.
21. Clark BF. The effects of oestrogen and progesterone on uterine cell division and epithelial morphology in spayed-hypophysectomized rats. J Endocrinol. 1973;56(2):341-342.
22. Tachi C, Tachi S, Lindner HR. Modification by progesterone of estradiol induced cell proliferation, RNA synthesis and oestradiol distribution in the rat uterus. J Repord Fertil. 1972;31(1):59-76.
23. Malumbres M, Barbacid M. To cycle or not to cycle: a decision in cancer. Nat Rev Cancer. 2001;1(3):222-231.
24. Obaya AJ, Sedivy JM. Regulation of cyclin-cdk activity in mammalian cells. Cell Mol Life Sci. 2002;59(1):126-142.
25. Kim S, Wu HG, Shin JH, Park HJ, Kim IA, Kim IH. Enhancement of radiation effect by flavopiridol in uterine cervix cancer cells. Cancer Res Treat. 2005;37(3):191-195.
26. Alonso M, Tamasdan C, Miller DC, Newcomb EW. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblatoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther. 2003;2(2):139-150.
27. Zhou P, Jiang W, Zhang YJ, et al. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human oesophageal cancer cells. Oncogene. 1995;11(3):571-580.
28. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol . 2006;24(11):1770-1783.
29. Patel V, Senderowicz AM, Pinto D Jr, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest. 1998;102(9):1674-1681.
30. Lechpammer M, Xu X, Ellis FH, Bhattacharaya N, Shapiro GI, Loda M. Flavopiridol reduces malignant transformation of the oesophageal mucosa in p27 knockout mice. Oncogene. 2005;24(10):1683-1688.
31. Sedlacek HH. Mechanism of action of flavopiridol. Crit Rev Oncol Hematol. 2001;38(2):139-170.
32. Berthet C, Kaldis P. Cell-specific responses to loss of cyclindependent kinases. Oncogene. 2007;26(31):4469-4477.
33. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 2008;14(2):159-169.
34. Shapiro GI. Preclinical and clinical development of the cyclin dependent kinase inhibitor flavopiridol. Clin Cancer Res . 2004;10(12 pt 2):4270-4275.
35. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308(5728):1589-1592.
36. Ding L, Xu J, Luo X, Chegini N. Gonadotropin releasing hormone and transforming growth factor beta activate mitogenactivated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab . 2004;89(11):5549-5557.
37. Arguello F, Alexander M, Sterry JA, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood. 1998;91(7):2482-2490.
38. Wirger A, Perabo FG, Burgemeister S, et al. Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer Res . 2005;25(6B):4341-4347.